Given that the results of the Sunwels investigation have been released, we think Amvis is likely to beat its H1 OP guidance. Along with attractive valuations [FY25 PER of 10.1x and PEG of 0.4x], analyst Hiroyuki Terada thinks this provides an opportunity to accumulate the shares.
Analyst Hiroyuki Terada updates his earnings on Amvis to reflect the change in the number of caregivers / nurses to patients, resulting in lower revenue per caregiver. While lowering his FY25~26 forecast OP, he introduces his FY27 targets. While valuations remain attractive, he remains cautious on the share price as peer Sunwels remains under investigation, therefore sentiment towards the healthcare providers remains volatile.
Specialized hospice provider CUC (9158 JT) announced better than expected FY24 Q2 results and yet has not revised up for the full year. Analyst Hiroyuki Terada explains the reasons why and notes he will review the outlook after his scheduled meeting with management on 5 Nov..
When the BoJ raised rates in March, it had been 17 years since it had last done so, though the world was very different then. While the July rate hike was unlikely to move the economic needle, the question now is what else might follow the subsequent financial market maelstrom. Pelham Smithers discusses the outlook for Japan’s macro environment, what new fiscal policies the new PM might introduce, how the BoJ might react and the all-important trend in corporate earnings. This then leads us to...
Small-cap specialist Hiroyuku Terada updates his forecasts for hospice facility operator CUC. He concludes that valuations remain attractive and notes that the -30% decline in the shares since the release of its new FY24 guidance on 24 April creates an opportunity to consider taking a position.
The general evaluation of AMVIS HOLDINGS (JP), a company active in the Health Care Providers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 8, 2022, the closing price was ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.